XML 47 R33.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Commitments and Contingencies - Additional Information (Details) - USD ($) |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 28, 2019 | Aug. 17, 2015 | Jan. 13, 2015 | Mar. 31, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2019 | Oct. 22, 2019 | Feb. 19, 2019 | Oct. 05, 2018 | Aug. 24, 2004
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | $ 7,893,000 | $ 14,521,000 | $ 19,411,000 | $ 41,427,000 |  |  |  |  |
Collaboration revenue |  |  |  |  | 2,911,000 | 398,000 | 2,911,000 | 398,000 |  |  |  |  |
MD Anderson Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Warrants |  |  |  |  |  |  |  |  |  | 3,333,333 |  |  |
Warrant exercise per share |  |  |  |  |  |  |  |  |  | $ 0.001 |  |  |
Warrant Expiry date |  |  |  |  |  |  |  |  |  | Dec. 31, 2026 |  |  |
MD Anderson Agreement and Worldwide License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement commencing date |  |  | Jan. 13, 2015 |  |  |  |  |  |  |  |  |  |
MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of historical costs |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |
Quarterly expense incurred |  |  |  |  | 300,000 | 0 | 700,000 | 0 |  |  |  |  |
Aggregate potential benchmark payments |  |  |  |  |  |  |  |  |  | 36,500,000 |  |  |
Payments due prior to the first marketing approval |  |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |
CRADA Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Quarterly expense incurred |  |  |  |  | 0 | 0 | 0 | 1,300,000 |  |  |  |  |
Contribution payable on per annum basis |  |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |
Obligations due under contract |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |
CAR Products [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum Royalty Amount |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000.0 |
The University of Texas MD Anderson Cancer Center and The Texas A & M University System |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone maximum payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,500,000
Payment under license agreement |  |  |  |  |  | 100,000 |  | 100,000 |  |  |  |  |
One time milestone payment |  |  |  |  | 2,500,000 |  | 2,500,000 |  |  |  |  |  |
The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Royalty [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Payment under license agreement |  |  |  |  | 0 | 0 | 0 | 0 |  |  |  |  |
License Agreement with the National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
License Expense |  |  |  |  | 100,000 | 300,000 | 500,000 | 600,000 |  |  |  |  |
License Agreement with the National Cancer Institute [Member] | One Time Benchmark Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
First benchmark payment | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum royalties amount payable | 300,000 |  |  |  |  |  |  |  |  |  |  |  |
Royalties amount payable thereafter | 100,000 |  |  |  |  |  |  |  |  |  |  |  |
Aggregate minimum annual royalties paid | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Description Of First Benchmark Payable | The first benchmark payment of $0.1 million was due upon the initiation of the Company's first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. The Company paid the first benchmark payment during the nine months ended September 30, 2022. |  |  |  |  |  |  |  |  |  |  |  |
Description Of option To terminate Agreement | The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event. |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination, notice period | 60 days |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | Performance Based Payments Member [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate Benchmark Payments Payable | $ 4,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | One Time Benchmark Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Potential Benchmark Payments Payable | 12,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | Post Marketing Approval [Member] | Performance Based Payments Member [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate Benchmark Payments Payable | 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | licensed products [Member] | One Time Benchmark Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum Sales Revenue On Which Benchmark Payments Payable | 1,000,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Minimum sales revenue on which benchmark payments payable | $ 250,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement With Solasia Pharma KK [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  | 400,000 |  | 400,000 |  |  |  |  |
Collaboration Agreement With Solasia Pharma KK [Member] | Royalty [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 0 | $ 0 | $ 0 | $ 0 |  |  |  |  |
Intrexon Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Annual License Fees |  |  |  |  |  |  |  |  |  |  |  | 100,000 |
Expected additional milestones payable |  |  |  |  |  |  |  |  |  |  |  | 52,500,000 |
Payment for historical costs of the licensed programs |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |
Intrexon Corporation | T-cell receptor |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum royalty amount |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000.0 |
Portion of income payable to related party |  |  |  |  |  |  |  |  |  |  |  | 20.00% |
Minimum | MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Maximum | MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Payments due prior to the first marketing approval for TCR products. + References No definition available. + Details
Name: | tcrt_AccrualsPriorToFirstMarketingApproval
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate Amount Potentially Reimburseable Amount. + References No definition available. + Details
Name: | tcrt_AggregateAmountPotentiallyReimburseableAmount
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents Aggregate Benchmark Payments Payable. + References No definition available. + Details
Name: | tcrt_AggregateBenchmarkPaymentsPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate minimum annual royalties paid. + References No definition available. + Details
Name: | tcrt_AggregateMinimumAnnualRoyaltiesPaid
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential benchmark payments. + References No definition available. + Details
Name: | tcrt_AggregatePotentialBenchmarkPayments
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Agreement termination notice period. + References No definition available. + Details
Name: | tcrt_AgreementTerminationNoticePeriod
Namespace Prefix: | tcrt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Annual License Fees + References No definition available. + Details
Name: | tcrt_AnnualLicenseFees
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments and Contingencies Disclosure [Line Items] + References No definition available. + Details
Name: | tcrt_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | tcrt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contribution payable on per annum basis. + References No definition available. + Details
Name: | tcrt_ContributionPayableOnPerAnnumBasis
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents Description Of First Benchmark Payable. + References No definition available. + Details
Name: | tcrt_DescriptionOfFirstBenchmarkPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones. + References No definition available. + Details
Name: | tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones
Namespace Prefix: | tcrt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The first benchmark payment due upon the initiation of the Company's first sponsored phase. + References No definition available. + Details
Name: | tcrt_InitialBenchmarkPaymentDue
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement commencing date. + References No definition available. + Details
Name: | tcrt_LicenseAgreementCommencingDate
Namespace Prefix: | tcrt_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense related to License payments. + References No definition available. + Details
Name: | tcrt_LicenseExpense
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount of additional milestones payable. + References No definition available. + Details
Name: | tcrt_MaximumAmountOfAdditionalMilestonesPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount of royalty payable. + References No definition available. + Details
Name: | tcrt_MaximumAmountOfRoyaltyPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount of royalty. + References No definition available. + Details
Name: | tcrt_MaximumRoyaltyAmount
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum Sales Revenue On Which Benchmark Payments Payable + References No definition available. + Details
Name: | tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | tcrt_MilestonePayment
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments maximum amount. + References No definition available. + Details
Name: | tcrt_MilestonePaymentsMaximumAmount
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents Minimum Royalties Amount Payable. + References No definition available. + Details
Name: | tcrt_MinimumRoyaltiesAmountPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum sales revenue on which benchmark payments payable. + References No definition available. + Details
Name: | tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Obligations due under contract. + References No definition available. + Details
Name: | tcrt_ObligationsDueUnderContract
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment for historical costs of the licensed programs. + References No definition available. + Details
Name: | tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment under license agreement. + References No definition available. + Details
Name: | tcrt_PaymentUnderLicenseAgreement
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of sub licensing income, attributable to related party. + References No definition available. + Details
Name: | tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty
Namespace Prefix: | tcrt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents Potential Benchmark Payments Payable. + References No definition available. + Details
Name: | tcrt_PotentialBenchmarkPaymentsPayable
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Quarterly expense incurred. + References No definition available. + Details
Name: | tcrt_QuarterlyExpenseIncurred
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties amount payable thereafter. + References No definition available. + Details
Name: | tcrt_RoyaltiesAmountPayableThereafter
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=tcrt_CARProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=tcrt_LicensedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=tcrt_TcellReceptorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |